Oncology Reviews最新文献_第10页

Physiopathology and diagnosis of cardiotoxicity in patients submitted to chemotherapy treatment. 接受化疗的患者的生理病理和心脏毒性诊断。

IF 3.1

Oncology Reviews Pub Date : 2019-02-01 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.383

Filipe C Marmelo, Cátia F R Sá

引用次数: 0

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma. 硼替佐米治疗复发或难治性多发性骨髓瘤患者的现实环境

IF 3.6

Oncology Reviews Pub Date : 2019-01-18 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.377

Shang-Yi Huang, Tsai-Yun Chen, Ching-Yuan Kuo, Yeu-Chin Chen, Sheng-Fung Lin, Ming-Chih Chang, Xinzhu Lv, Betty Yang, Cheng-Shyong Chang

{"title":"Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma.","authors":"Shang-Yi Huang, Tsai-Yun Chen, Ching-Yuan Kuo, Yeu-Chin Chen, Sheng-Fung Lin, Ming-Chih Chang, Xinzhu Lv, Betty Yang, Cheng-Shyong Chang","doi":"10.4081/oncol.2019.377","DOIUrl":"https://doi.org/10.4081/oncol.2019.377","url":null,"abstract":"Bortezomib is a proteasome inhibitor, approved for treating newly diagnosed and relapsed multiple myeloma (MM). This realworld, multicenter, observational, non-interventional study of bortezomib was designed to collect and analyze prospective data in Taiwanese patients with relapsed or refractory MM. The primary endpoints included clinical effectiveness outcomes (disease response, disease progression [PD], time-to-response, time-toprogression, response duration, and overall survival [OS]). Secondary endpoints were safety and healthcare resource utilization. Total 100 patients (median [range] age 64.9 [37.0-85.5] years) were enrolled; 47 patients completed the study. Of the withdrawn patients (n=53), there were 48 deaths (PD-related death: n=35, adverse events [AEs]-related: n=12, other reason: n=1), and 5 due to loss to follow-up. Four patients in Cycle 1, 6 patients each in Cycle 2 and 5, 7 in Cycle 3, 10 patients in Cycle 4, 5 patients in Cycle 6, and 3 patients each in Cycle 7 and 8 achieved overall response during the study. Time-to-response was 4.68 months (95%CI: 3.2, NE) and response duration was 10.08 months (95%CI: 2.3, 28.6). Median OS was 9.8 months (95%CI: 3.8, 13.7), and median time-to-progression was 11.3 months (95%CI: 6.2, 20.2). Most common non-hematological AEs were diarrhea (n=32) and hypoesthesia (n=25); most common hematological AE was thrombocytopenia (n=18). Efficacy and safety profile of bortezomib in Taiwanese patients with MM was similar to global and other Asian population. Study provides a critical insight on use of bortezomib in realworld clinical practice, which can be helpful for Taiwanese healthcare providers' decision-making processes.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"377"},"PeriodicalIF":3.6,"publicationDate":"2019-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.377","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37045057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: A systematic review of the literature. 宫颈癌伴肾积水患者的生存结局:文献系统综述。

IF 3.6

Oncology Reviews Pub Date : 2019-01-15 eCollection Date: 2019-01-14 DOI: 10.4081/oncol.2019.387

Vasilios Pergialiotis, Ioannis Bellos, Nikolaos Thomakos, Dimitrios Haidopoulos, Despina N Perrea, Konstantinos Kontzoglou, Georgios Daskalakis, Alexandros Rodolakis

{"title":"Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: A systematic review of the literature.","authors":"Vasilios Pergialiotis, Ioannis Bellos, Nikolaos Thomakos, Dimitrios Haidopoulos, Despina N Perrea, Konstantinos Kontzoglou, Georgios Daskalakis, Alexandros Rodolakis","doi":"10.4081/oncol.2019.387","DOIUrl":"https://doi.org/10.4081/oncol.2019.387","url":null,"abstract":"Hydronephrosis is a sign of advanced stage disease in patients with cervical cancer. Its presence is believed to negatively affect the survival of patients. To date, however, consensus in this field is still lacking. The purpose of the present systematic review is to gather the available data and to provide directions for future research in the field. We systematically searched Medline, Scopus, Clinicaltrials.gov, EMBASE, Cochrane Central Register of Controlled Trials CENTRA and Google Scholar databases from inception till June 2018. Overall, 22 studies were included in the present systematic review that evaluated outcomes from 8521 patients with cervical cancer. The findings of our systematic review support that hydronephrosis negatively affects the overall survival of cervical cancer patients. Specifically, the reported 5- year OS hazards ratio for hydronephrosis ranged between 1.34 and 3.74. Outcomes concerning the disease-free survival of these patients were, however, less discrete. None of the included studies reported whether the decreased survival of patients with hydronephrosis was attributed to complications of obstructive uropathy such as uremia and sepsis. Thus, it remains, to date, unclear whether placement of ureteral stents or percutaneous nephrostomy may actually benefit these patients. More studies are needed to evaluate the actual impact of hydronephrosis on survival rates at the various stages of cervical cancer and to help establish consensus regarding the optimal mode of management of these patients.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"13 1","pages":"387"},"PeriodicalIF":3.6,"publicationDate":"2019-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2019.387","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36952674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Breast cancer, human immunodeficiency virus and highly active antiretroviral treatment; implications for a high-rate seropositive region. 癌症、人类免疫缺陷病毒和高活性抗逆转录病毒治疗；对高血清阳性区域的影响。

IF 3.6

Oncology Reviews Pub Date : 2019-01-14 DOI: 10.4081/oncol.2019.376

Subash Chirkut

引用次数: 0

Myelodysplastic syndrome from theoretical review to clinical application view. 骨髓增生异常综合征从理论综述到临床应用。

IF 3.6

Oncology Reviews Pub Date : 2018-12-07 DOI: 10.4081/oncol.2018.397

Amrallah A Mohammad

引用次数: 25

The quality of guidelines in non-pharmacological prevention and management of chemotherapy-induced neuropathy: A review. 化疗引起的神经病变的非药物预防和管理指南的质量:综述。

IF 3.6

Oncology Reviews Pub Date : 2018-10-18 eCollection Date: 2018-07-04 DOI: 10.4081/oncol.2018.359

Shahin Salarvand, Simin Hemati, Payman Adibi, Fariba Taleghani

引用次数: 4

Vitamin D and its receptor polymorphisms: New possible prognostic biomarkers in leukemias. 维生素D及其受体多态性:白血病可能的新预后生物标志物。

IF 3.6

Oncology Reviews Pub Date : 2018-10-08 eCollection Date: 2018-07-04 DOI: 10.4081/oncol.2018.366

Seyed Mohammad Sadegh Pezeshki, Ali Amin Asnafi, Abbas Khosravi, Mohammad Shahjahani, Shirin Azizidoost, Saeid Shahrabi

{"title":"Vitamin D and its receptor polymorphisms: New possible prognostic biomarkers in leukemias.","authors":"Seyed Mohammad Sadegh Pezeshki, Ali Amin Asnafi, Abbas Khosravi, Mohammad Shahjahani, Shirin Azizidoost, Saeid Shahrabi","doi":"10.4081/oncol.2018.366","DOIUrl":"https://doi.org/10.4081/oncol.2018.366","url":null,"abstract":"Several factors such as chromosomal translocations, gene mutations, and polymorphisms are involved in the pathogenesis of leukemia/lymphoma. Recently, the role of vitamin D (VD) and vitamin D receptor (VDR) polymorphisms in hematologic malignancies has been considered. In this review, we examine the possible role of VD levels, as well as VDR polymorphisms as prognostic biomarkers in leukemia/lymphoma. Relevant English language literature were searched and retrieved from Google Scholar search engine (1985-2017). The following keywords were used: vitamin D, vitamin D receptor, leukemia, lymphoma, and polymorphism. Increased serum levels of VD in patients with leukemia are associated with a better prognosis. However, low VD levels are associated with a poor prognosis, and VDR polymorphisms in various leukemias can have prognostic value. VD biomarker can be regarded as a potential prognostic factor for a number of leukemias, including acute myeloblastic leukemia (AML), chronic lymphoblastic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). There is a significant relationship between different polymorphisms of VDR (including Taq I and Fok I) with several leukemia types such as ALL and AML, which may have prognostic value.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"12 2","pages":"366"},"PeriodicalIF":3.6,"publicationDate":"2018-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2018.366","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36703770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Expression of CD markers in JAK2^V617F positive myeloproliferative neoplasms: Prognostic significance. JAK2V617F阳性骨髓增生性肿瘤中CD标志物的表达:预后意义

IF 3.6

Oncology Reviews Pub Date : 2018-10-02 eCollection Date: 2018-07-04 DOI: 10.4081/oncol.2018.373

Saeid Shahrabi, Ali Ehsanpour, Somayyeh Heidary, Mohammad Shahjahani, Masumeh Maleki Behzad

{"title":"Expression of CD markers in JAK2V617F positive myeloproliferative neoplasms: Prognostic significance.","authors":"Saeid Shahrabi, Ali Ehsanpour, Somayyeh Heidary, Mohammad Shahjahani, Masumeh Maleki Behzad","doi":"10.4081/oncol.2018.373","DOIUrl":"https://doi.org/10.4081/oncol.2018.373","url":null,"abstract":"Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by the presence of JAK2V617F mutation. Thrombohemorrhagic as well as autoimmune or inflammatory phenomena are common clinical outcomes of these disorders. Recent studies have shown that abnormality in frequency and function of blood cells manifested by an alteration in CD markers' expression patterns play a key role in these complications. So, there may be a relationship between CD markers' expressions and prognosis of JAK2V617F positive MPNs. Therefore, in this review, we have focused on these abnormalities from the perspective of changing expressions of CD markers and assessment of the relationship between these changes with prognosis of JAK2V617F positive MPNs. It can be stated that the abnormal expression of a large number of CD markers can be used as a prognostic biomarker for clinical outcomes including thrombohememorrhagic events, as well as autoimmune and leukemic transformation in JAK2V617F positive MPNs. Considering the possible role of CD markers' expressions in JAK2V617F MPNs prognosis, further studies are needed to confirm the relationship between the expression of CD markers with prognosis to be able to find an appropriate therapeutic approach via targeting CD markers.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"12 2","pages":"373"},"PeriodicalIF":3.6,"publicationDate":"2018-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2018.373","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36703772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Advanced pancreatic cancer: The standard of care and new opportunities. 晚期胰腺癌:治疗标准和新机遇。

IF 3.6

Oncology Reviews Pub Date : 2018-09-14 eCollection Date: 2018-07-04 DOI: 10.4081/oncol.2018.370

Amrallah A Mohammad

引用次数: 10

A survey of early and advanced gastric cancer treatment by surgeons in Thailand. 泰国外科医生对早期和晚期胃癌治疗的调查。

IF 3.6

Oncology Reviews Pub Date : 2018-08-28 eCollection Date: 2018-07-04 DOI: 10.4081/oncol.2018.369

Prasit Mahawongkajit, Prakitpunthu Tomtitchong

{"title":"A survey of early and advanced gastric cancer treatment by surgeons in Thailand.","authors":"Prasit Mahawongkajit, Prakitpunthu Tomtitchong","doi":"10.4081/oncol.2018.369","DOIUrl":"https://doi.org/10.4081/oncol.2018.369","url":null,"abstract":"This study shows the first survey of patterns about surgeons' approaches and current practices in early and advanced gastric cancer in Thailand. Gastric cancer is a significant health problem worldwide. International guidelines for treatment differ in their recommendations including the accompanying therapy, but the condition is potentially curable. Surgeons have played an important role in Thailand but the limitation of institutional resources and the practices for gastric cancer vary between treatment options. The aim of this study is to investigate the current practices and approaches of Thai surgeons in relation to early and advanced gastric cancer treatment. A survey was conducted on 112 surgeons who claimed to have performed clinical practice upon gastric cancer patients. Information was collected on participant demographic data, the practices approaches in early and advanced stage without metastasis and the preferable adjuvant chemotherapy. The majority of participants were 100 general surgeons (89.4%). The preferred early gastric cancer treatment proved to be endoscopic resection 83.9%, cT1bN0 group preferred laparoscopic surgery 75.9%, cT2-T4aN0 group preferred open surgery 67.8%, cT4bN0 group preferred open surgery with En bloc resection 85.7% and cN+ group preferred open surgery 70.5%. For adjuvant treatment with chemotherapy, the study showed the surgeons who prescribed and treated by themselves was 41.9%. The preferred adjuvant regimens were S-1 50.9% and capecitabine and oxaliplatin 31.3%. This study is the first survey of the patterns of surgeons' approaches and current practices in early and advanced gastric cancer in Thailand.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"12 2","pages":"369"},"PeriodicalIF":3.6,"publicationDate":"2018-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4081/oncol.2018.369","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36604261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2